Prognostic Significance of HER2 Expression for Gastric Cancer With Clinically Para-aortic Lymph Node Metastasis

被引：3
作者：
Arigami, Takaaki [1 ]
Matsushita, Daisuke [2 ]
Okubo, Keishi [2 ]
Sasaki, Ken [2 ]
Tsuruda, Yusuke [2 ]
Kita, Yoshiaki [2 ]
Mori, Shinichiro [2 ]
Yanagita, Shigehiro [2 ]
Uenosono, Yoshikazu [2 ]
Kurahara, Hiroshi [2 ]
Ohtsuka, Takao [1 ,2 ]
机构：
[1] Kagoshima Univ, Dept Oncobiol Surg, Grad Sch Med & Dent Sci, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan
[2] Kagoshima Univ, Dept Digest Surg Breast & Thyroid Surg, Grad Sch Med & Dent Sci, Kagoshima, Japan
来源：
ANTICANCER RESEARCH | 2021年 / 41卷 / 06期
关键词：
Gastric cancer; para-aortic lymph node metastasis; trastuzumab; prognosis; HER2; expression; NEOADJUVANT CHEMOTHERAPY; LARGE-SCALE; MULTICENTER; CISPLATIN; SURVIVAL; IMPACT; S-1;
D O I：
10.21873/anticanres.15094
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background/Aim: To determine the prognostic utility of trastuzumab-based chemotherapy based on human epidermal growth factor receptor 2 (HER2) expression in patients with para-aortic lymph node (PAN) metastasis from gastric cancer. Patients and Methods: A total of 41 patients with clinical PAN metastasis from gastric cancer who underwent chemotherapy were retrospectively enrolled. Results: Eighteen (43.9%) patients had HER2-positive tumors and consequently, received trastuzumab-based chemotherapy. A total of 11 patients underwent surgery. HER2 status was significantly correlated with the number of distant metastatic sites, the presence or absence of trastuzumab-based chemotherapy, and the presence or absence of gastrectomy. HER2-positive patients had significantly better prognosis than HER2-negative patients. Multivariate analysis identified age and trastuzumab-based chemotherapy based on HER2 status as an independent prognostic factor. Conclusion: Assessing HER2 expression and subsequent trastuzumab-based chemotherapy can be an effective method for determining the prognosis of patients with PAN metastasis from gastric cancer.
引用
收藏
页码：3099 / 3107
页数：9
相关论文
共 26 条
[11]   Japanese gastric cancer treatment guidelines 2018 (5th edition) [J].
Japanese Gastric Cancer Association .
GASTRIC CANCER, 2021, 24 (01) :1-21
[12]   An integrated analysis of two phase II trials (JCOG0001 and JCOG0405) of preoperative chemotherapy followed by D3 gastrectomy for gastric cancer with extensive lymph node metastasis [J].
Katayama, Hiroshi ;
Tsuburaya, Akira ;
Mizusawa, Junki ;
Nakamura, Kenichi ;
Katai, Hitoshi ;
Imamura, Hiroshi ;
Nashimoto, Atsushi ;
Fukushima, Norimasa ;
Sano, Takeshi ;
Sasako, Mitsuru .
GASTRIC CANCER, 2019, 22 (06) :1301-1307
[13]  
Kim J, 2014, ANTICANCER RES, V34, P3807
[14]   Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer [J].
Kurokawa, Yukinori ;
Matsuura, Nariaki ;
Kimura, Yutaka ;
Adachi, Shinichi ;
Fujita, Junya ;
Imamura, Hiroshi ;
Kobayashi, Kenji ;
Yokoyama, Yuhki ;
Shaker, Mohammed Nouri ;
Takiguchi, Shuji ;
Mori, Masaki ;
Doki, Yuichiro .
GASTRIC CANCER, 2015, 18 (04) :691-697
[15]   The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature [J].
Lei, Yu-ying ;
Huang, Jin-yu ;
Zhao, Qiong-rui ;
Jiang, Nan ;
Xu, Hui-mian ;
Wang, Zhen-ning ;
Li, Hai-qing ;
Zhang, Shi-bo ;
Sun, Zhe .
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2017, 15
[16]   HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial) [J].
Matsumoto, Tomohiro ;
Sasako, Mitsuru ;
Mizusawa, Junki ;
Hirota, Seiichi ;
Ochiai, Atsushi ;
Kushima, Ryoji ;
Katai, Hitoshi ;
Tanaka, Yoichi ;
Fukushima, Norimasa ;
Nashimoto, Atsushi ;
Tsuburaya, Akira .
GASTRIC CANCER, 2015, 18 (03) :467-475
[17]   Assessment of Systemic Inflammatory Response and Nutritional Markers in Patients With Trastuzumab-treated Unresectable Advanced Gastric Cancer [J].
Namikawa, Tsutomu ;
Maeda, Masahiro ;
Yokota, Keiichiro ;
Tanioka, Nobuhisa ;
Fukudome, Ian ;
Iwabu, Jun ;
Munekage, Masaya ;
Uemura, Sunao ;
Maeda, Hiromichi ;
Kitagawa, Hiroyuki ;
Kobayashi, Michiya ;
Hanazaki, Kazuhiro .
IN VIVO, 2020, 34 (05) :2851-2857
[18]   HER-2/neu amplification is an independent prognostic factor in gastric cancer [J].
Park, Dong Il ;
Yun, Jung Won ;
Park, Jung Ho ;
Oh, Suk Joong ;
Kim, Hong Joo ;
Cho, Yong Kyun ;
Il Sohn, Chong ;
Jeon, Woo Kyu ;
Kim, Byung Ik ;
Yoo, Chang Hak ;
Son, Byung Ho ;
Cho, Eun Yoon ;
Chae, Seoung Wan ;
Kim, Eo-Jin ;
Sohn, Jin Hee ;
Ryu, Seung Ho ;
Sepulveda, Antonia R. .
DIGESTIVE DISEASES AND SCIENCES, 2006, 51 (08) :1371-1379
[19]   Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China [J].
Shen, Guo-Shuang ;
Zhao, Jiu-Da ;
Zhao, Jun-Hui ;
Ma, Xin-Fu ;
Du, Feng ;
Kan, Jie ;
Ji, Fa-Xiang ;
Ma, Fei ;
Zheng, Fang-Chao ;
Wang, Zi-Yi ;
Xu, Bing-He .
WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (23) :5406-5414
[20]   Changes in HER2 Expression and Amplification Status Following Preoperative Chemotherapy for Gastric Cancer [J].
Shu, Sei ;
Iimori, Makoto ;
Nakanishi, Ryota ;
Jogo, Tomoko ;
Saeki, Hiroshi ;
Oki, Eiji ;
Maehara, Yoshihiko .
IN VIVO, 2018, 32 (06) :1491-1498
123